Tilray Brands, Inc. (TLRY.TO)

Revenue growth above 1.5x CRON.TO's 21.04%. David Dodd would confirm if the firm has a unique advantage driving sales higher.

Positive gross profit growth while CRON.TO is negative. John Neff would see a clear operational edge over the competitor.

Positive EBIT growth while CRON.TO is negative. John Neff might see a substantial edge in operational management.

Positive operating income growth while CRON.TO is negative. John Neff might view this as a competitive edge in operations.

Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.

Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.

Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

Positive OCF growth while CRON.TO is negative. John Neff would see this as a clear operational advantage vs. the competitor.

10Y OCF/share CAGR above 1.5x CRON.TO's 43.60%. David Dodd would check if a superior product mix or cost edge drives this outperformance.

5Y OCF/share CAGR above 1.5x CRON.TO's 43.60%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.

3Y OCF/share CAGR above 1.5x CRON.TO's 43.60%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.

Net income/share CAGR above 1.5x CRON.TO's 70.57% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.

5Y net income/share CAGR above 1.5x CRON.TO's 70.57%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.

3Y net income/share CAGR above 1.5x CRON.TO's 70.57%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.

10Y equity/share CAGR above 1.5x CRON.TO's 57.20%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.

5Y equity/share CAGR above 1.5x CRON.TO's 57.20%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.

3Y equity/share CAGR above 1.5x CRON.TO's 57.20%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.

AR growth is negative/stable vs. CRON.TO's 127.22%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.

Asset growth above 1.5x CRON.TO's 37.69%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.

BV/share growth above 1.5x CRON.TO's 51.46%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.

No Data available this quarter, please select a different quarter.

We expand SG&A while CRON.TO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.